BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide, sequence GEPPPGKPADDAGLV, derived from a protective sequence identified in human gastric juice. Since its initial characterization by Predrag Sikiric's group at the University of Zagreb in the early 1990s, it has accumulated one of the largest preclinical evidence bases of any research peptide, spanning wound healing, gastrointestinal protection, musculoskeletal repair, and CNS modulation.
The compound is pharmacologically unusual in several respects. It shows activity by multiple routes of administration. It affects a remarkable breadth of tissue types. And its effects look cytoprotective rather than pharmacological in the traditional sense; it modulates endogenous repair processes rather than substituting for a specific molecule. Examining the proposed mechanisms in some depth helps explain why.
Mechanism of Action
BPC-157 does not appear to exert its effects through a single identified receptor. The evidence points to multiple, partially overlapping pathways:
- VEGFR2 and angiogenesis: Upregulates vascular endothelial growth factor receptor 2 and focal adhesion kinase (FAK), accelerating capillary formation. This angiogenic activity is central to its tissue repair effects — new vascularity brings oxygen and nutrients to healing tissue.
- Egr1 transcription factor: The early growth response gene 1 is consistently upregulated in BPC-157 studies. Egr1 drives collagen synthesis, fibronectin production, and other extracellular matrix components critical for structural repair.
- Nitric oxide modulation: Interacts with both endothelial NOS (eNOS) and neuronal NOS (nNOS) pathways. Effects appear context-dependent — pro-NO in vasculature, anti-inflammatory blunting in other contexts.
- GH receptor interaction: Evidence suggests BPC-157 potentiates growth hormone signaling at or near the GH receptor level, which may contribute to its systemic regenerative profile.
- CNS neurotransmission: Modulates dopamine and serotonin systems; relevant to its observed effects on mood, addiction models, and brain protection after traumatic injury.
- Interaction with FGFR1: Some studies suggest interaction with fibroblast growth factor receptor 1, involved in tissue repair and cell proliferation.
Gastrointestinal Protection: The Strongest Evidence
Gastrointestinal protection is the most replicated finding in BPC-157 research, which is consistent with its derivation from gastric tissue. The evidence spans multiple models of GI injury:
- NSAID-induced ulceration (aspirin, indomethacin, ethanol): BPC-157 consistently reduces ulcer index scores versus controls
- Cysteamine-induced duodenal ulcers: BPC-157 accelerates healing in both prevention and treatment protocols
- Acetic acid colitis and TNBS-induced Crohn's-like inflammation: anti-inflammatory and mucosal healing effects
- Short bowel syndrome models: improved adaptation and intestinal regrowth
- Anastomosis healing: superior healing of surgically created intestinal connections
Uniquely, BPC-157 shows GI protective activity by both injectable and oral routes in rodent models. That's unusual; most peptides get degraded by gastric acid before reaching target tissue. The oral activity has been attributed to local action on GI epithelium rather than requiring systemic absorption, though the exact mechanism remains debated.
Musculoskeletal Repair Evidence
Tendon, ligament, and muscle healing is the second major area of research interest. Rodent models of surgically transected tendons, crushed muscles, and ligament ruptures consistently show accelerated healing in BPC-157 treated animals: faster regain of mechanical strength, superior collagen fiber organization on histology, and improved functional recovery.
BPC-157 consistently accelerated tendon-to-bone healing, with superior collagen organization and biomechanical strength at the repair site compared to controls, in a dose-dependent manner.
— Chang CH et al., Journal of Applied Physiology, 2011
The tendon-to-bone healing model is particularly relevant because this interface (the enthesis) is the slowest-healing tissue in the musculoskeletal system and is the site of most chronic tendon injuries. BPC-157's demonstrated efficacy at this interface in multiple studies explains the high interest in this compound among athletes and active individuals.
Central Nervous System Effects
BPC-157's CNS effects span several distinct areas of research. In traumatic brain injury models, systemic BPC-157 reduces behavioral deficits and histological damage, suggesting neuroprotective properties consistent with its angiogenic and anti-inflammatory mechanisms. In dopaminergic models, BPC-157 modulates dopamine release and receptor sensitivity, with potential relevance to addiction, movement disorders, and mood.
Perhaps most striking are studies in models of systemic organ damage-induced encephalopathy: BPC-157 administered after hepatic or renal injury appears to protect the brain from secondary neurological dysfunction. This multi-organ protective effect suggests a systemic signaling function beyond local repair.
Research Gaps and Critical Limitations
- No human clinical trials published: No Phase 2 or Phase 3 RCTs in humans have been completed or published. This is the single most important limitation.
- Research group concentration: The vast majority of BPC-157 research comes from Sikiric's Zagreb group. Independent replication is far more limited than the total study count suggests.
- Receptor identification: The primary molecular receptor(s) of BPC-157 have not been conclusively identified, complicating mechanistic interpretation.
- Human pharmacokinetics: Absorption, distribution, metabolism, and excretion in humans have not been formally studied. The plasma half-life, bioavailability by different routes, and active metabolites are unknown.
- FDA compounding ban (2023): BPC-157 was added to the FDA's list of bulk drug substances that cannot be compounded, eliminating pharmaceutical-grade access in the U.S. and signaling regulatory concern about the evidence base.
- Pro-angiogenic theoretical risk: VEGFR2 upregulation is the same pathway exploited by tumors for vascular supply. Whether BPC-157 could accelerate growth of pre-existing tumors is a real theoretical concern that has not been adequately studied.
BPC-157 is a stable gastric pentadecapeptide, a truly novel modality of multi-target therapy that acts simultaneously on many targets to provide an integrated physiological response.
— Sikiric P et al., Current Pharmaceutical Design, 2018
Clinical Trial Status
Revive Medical has initiated Phase I/II clinical trials for BPC-157 in inflammatory bowel disease, making this the first formal Western clinical investigation of the compound in humans. Results are expected but not yet published as of early 2026. If Phase I safety data is favorable and Phase II shows efficacy signals, BPC-157 could move toward legitimate pharmaceutical development — which would be the most important milestone in the compound's research history.
References & primary sources
BPC-157 has a substantial preclinical literature, almost entirely from the Sikiric group in Zagreb. The selected sources below cover the mechanism and tissue-healing claims in the article body. The full BPC-157 literature is indexed on PubMed under 'BPC 157' and 'pentadecapeptide BPC'.
- Sikiric P, Seiwerth S, Rucman R, et al. (2010) Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 16:1224-1234.
- Chang CH, Tsai WC, Hsu YH, Pang JS. (2014) The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology 117:1230-1237.
- Cerovecki T, Bojanic I, Brcic L, et al. (2010) Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research 28:1155-1161.
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. (2008) Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. Inflammation Research 57:205-210.
- Sikiric P, Seiwerth S, Rucman R, et al. (2016) Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology 14:857-865.
Questions and answers
Does BPC-157 act through a single identified receptor?
No. The evidence points to multiple partially overlapping pathways rather than one receptor, including VEGFR2 and focal adhesion kinase, the Egr1 transcription factor, nitric oxide modulation, growth hormone receptor signalling and CNS neurotransmission. The primary molecular receptor has not been conclusively identified, which complicates mechanistic interpretation.
Which BPC-157 finding is the most replicated?
Gastrointestinal protection, which is consistent with the peptide's derivation from gastric tissue. The preclinical evidence spans NSAID-induced ulceration, cysteamine-induced duodenal ulcers, acetic acid and TNBS colitis models, short bowel syndrome models and anastomosis healing.
Have human clinical trials of BPC-157 been published?
No. No Phase 2 or Phase 3 randomised controlled trials in humans have been completed or published, which is the single most important limitation on the evidence base. Revive Medical has initiated Phase I/II trials in inflammatory bowel disease, and results were not yet published as of early 2026.
What are the main limitations of the BPC-157 literature?
The absence of published human trials. Concentration of the literature in one research group in Zagreb, so independent replication is more limited than the total study count suggests. Unidentified receptors. No formal human pharmacokinetics. The 2023 FDA decision placing it on the list of bulk drug substances that cannot be compounded. And the theoretical concern that VEGFR2 upregulation is the same pathway tumours use for vascular supply, which has not been adequately studied.